Vicora
Vicora is a pre-commercialization medical device company developing the Vibrato thrombectomy catheter, the first catheter with integrated distal tip vibration, for clot removal in Deep Vein Thrombosis and Pulmonary Embolism procedures targeting hospital interventional radiology and cardiology departments.
- Company typePrivate
- Founded2020
- HeadquartersBuffalo, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vicora does
Vicora is a privately held, pre-commercialization medical device company headquartered in Buffalo, New York, developing the Vibrato thrombectomy system, described as the world's first catheter with integrated distal tip vibration. The system targets mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures, addressing a US market of approximately 900,000 annual DVT cases, a 15% mortality rate in hospitalized PE patients, and a documented 5% incidence of clot fragment migration ("lollipopping" or "corking") during treatment. The device is designed to require no additional capital equipment, with optimized trackability intended to ease navigation through vascular anatomy.
Vicora completed its GLP pre-clinical study in January 2026 but has not yet received FDA clearance and is not approved for sale in any country. The intended go-to-market is direct enterprise sales to hospital interventional radiology and interventional cardiology departments performing thrombectomy procedures. The company is structured as the first portfolio company of Egret Healthcare Ventures, with a team of approximately 10 members covering CEO (Shawn Patterson), Executive Chairman (Bill Maggio), CFO, Chief Scientific Officer, Corporate Counsel, Quality & Regulatory Officer, Director of Engineering, Director of Administration, Director of Commercialization, and Corporate Relations.
The business model is currently one of capital-funded R&D rather than product revenue. Vicora has raised approximately $3.6M in a May 2025 round and filed a $6M SEC Form D offering (with $3.4M sold as of the filing), supplemented by non-dilutive funding from the University at Buffalo Center for Advanced Technology (UB CAT). Strategic partners include the Jacobs Institute, Yageo Group KEMET, Resolution Medical, Hemologyx, KCRI, and Rookery Labs, and the company has assembled a clinical advisory board drawn from Mayo Clinic, Karolinska University Hospital, UCLA, Montefiore Medical Center, and the Gates Vascular Institute.
Vicora firmographics
Firmographics- Name
- Vicora
- Legal name
- Vicora, Inc.
- Website
- https://vicora.net
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vicora is a pre-commercialization medical device company developing the Vibrato thrombectomy catheter, the first catheter with integrated distal tip vibration, for clot removal in Deep Vein Thrombosis and Pulmonary Embolism procedures targeting hospital interventional radiology and cardiology departments.
- Ownership category
- akta.pro rank
Vicora industry classification
Industry- Product category
- Vascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
- akta.pro secondary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
Keywords
Where Vicora is headquartered
LocationHeadquarters
- HQ city
- Buffalo
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vicora business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: Pre-commercialization medical device company planning to sell thrombectomy catheters and associated products to hospitals and interventional radiology/cardiology departments upon FDA clearance.
- Securities Offering: SEC Form D filing for equity and pooled investment fund interests offering, with $6 million total offering amount and $3.4 million sold as of the filing date.
Go-to-market motion1 record
Marketing channels3 records
Vicora product offering
Product offeringCore offering
Vicora is developing the Vicora Vibrato Thrombectomy System, described as the world's first catheter with an integrated distal tip vibration mechanism designed for mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures. The device is intended for use by interventional radiologists and interventional cardiologists in hospital settings, and requires no additional capital equipment for operation. The product is currently in pre-clinical testing (GLP study completed January 2026) and is not yet FDA cleared or commercially available.
Product overview
Vicora offers a single unified product: the Vicora Vibrato Thrombectomy System. This is the world's first catheter with an integrated distal tip vibration mechanism designed for clot removal procedures. The system targets Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) treatment. The device is currently in pre-clinical testing (GLP study completed January 2026) and has not received FDA clearance or approval. It is not available for commercial sale in any country.
Differentiator
Problem solved
Functional benefit
Products and services
- Vicora Vibrato Thrombectomy System The Vicora Vibrato is a thrombectomy catheter featuring an integrated vibrating distal tip mechanism intended for mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures. The device is designed for hospital interventional radiology and interventional cardiology departments, offers optimized trackability through vascular anatomy, and operates without requiring additional capital equipment. The product is currently in pre-clinical testing and has not received FDA clearance.
Quantifiable outcome
- 900,000 DVT cases annually in the US creating substantial addressable market
- +2 more outcomes
Companies that use Vicora
Customer profileSegments2 records
Ideal customer profiles1 record
Vicora technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Vicora partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- University at Buffalo (UB CAT)coreUB CAT (Center for Advanced Technology) awarded Vicora an R&D collaboration award in September 2024. The partnership provides funding and research support for life sciences development. Vicora also received UB CAT funding in December 2023.
- Jacobs InstitutecoreStrategic partner listed on Vicora's website alongside other industry partners. The Jacobs Institute is focused on vascular innovation and medical device development, aligned with Vicora's thrombectomy technology focus.
- Yageo Group KEMETcoreStrategic partner providing electronic components expertise. KEMET is a leading global manufacturer of electronic components that may support Vicora's catheter technology development.
- Resolution MedicalcoreStrategic partner listed on Vicora's website, specializing in medical device development with focus on interventional products.
- Rookery LabsminorListed as a strategic partner on Vicora's website, providing potential commercialization or business development support.
- HemologyxminorStrategic partner focused on hematology expertise relevant to Vicora's clot removal technology for DVT and PE treatment.
- KCRI (Klein Cutler Research Institute)minorListed as a strategic partner on Vicora's website, providing research institute collaboration for medical device development.
- Eric RudieminorListed as a strategic partner on Vicora's website, providing industry expertise in medical device development.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Vicora competitors and assessment
Company assessmentDirect peers
- Penumbra: Penumbra's Indigo aspiration system is a leading mechanical thrombectomy platform for PE and DVT, directly competing with Vicora's Vibrato in the same hospital interventional radiology and cardiology call points.
- Inari Medical (Stryker): Inari's FlowTriever (PE) and ClotTriever (DVT) are purpose-built mechanical thrombectomy devices and the closest direct competitors to Vicora Vibrato in the venous thromboembolism space.
- AngioDynamics: AngioDynamics offers the AlphaVac and AngioVac mechanical thrombectomy systems, addressing PE and venous clot removal in the same hospital departments Vicora targets.
- Argon Medical Devices: Argon manufactures the Option Elite and other venous intervention devices used for thrombectomy, positioning it as a competing supplier in DVT/PE clot-removal procedures.
Broad incumbents
- Stryker: Through its 2025 acquisition of Inari Medical, Stryker is now a major player in venous mechanical thrombectomy; it also operates broader neurovascular and vascular franchises that overlap with Vicora's procedural category.
- Boston Scientific: Boston Scientific has peripheral vascular and interventional cardiology franchises that compete in hospital procedural suites where thrombectomy is performed, even though it does not lead in mechanical PE/DVT.
- Teleflex: Teleflex markets Arrow vascular access and interventional catheters used in the same hospital IR/cardiology settings, representing an incumbent catheter vendor at accounts Vicora would target.
- Medtronic: Medtronic has peripheral and coronary interventional portfolios that overlap with the procedural call points and purchasing relationships Vicora will rely on at hospital systems.
- Johnson & Johnson (Cerenovus): Cerenovus, J&J's neurovascular business, is a leading player in catheter-based clot retrieval (notably for stroke), bringing catheter thrombectomy R&D and sales capability adjacent to Vicora's venous use cases.
Emerging players
- Imperative Care: Imperative Care is developing next-generation catheter-based vascular intervention technologies, with overlapping R&D culture and similar hospital call points in interventional radiology and cardiology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Vicora social profiles
Digital presenceVicora financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vicora leadership team
Management profileNumber of profiles
Profiles10 records
Vicora funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vicora M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vicora
What does Vicora do?
Vicora is developing the Vicora Vibrato Thrombectomy System, described as the world's first catheter with an integrated distal tip vibration mechanism designed for mechanical clot removal in Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) procedures. The device is intended for use by interventional radiologists and interventional cardiologists in hospital settings, and requires no additional capital equipment for operation. The product is currently in pre-clinical testing (GLP study completed January 2026) and is not yet FDA cleared or commercially available.
Is Vicora a public or private company?
Vicora is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vicora founded?
Vicora was founded in 2020. It employs 11 to 50 people.
Where is Vicora based?
Vicora is headquartered in Buffalo, United States, in the North America region.
How does Vicora make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are securities Offering.
Who are Vicora's main competitors?
Direct peers on record are Penumbra, Inari Medical (Stryker), AngioDynamics and Argon Medical Devices. Broad incumbents are Stryker, Boston Scientific, Teleflex, Medtronic and Johnson & Johnson (Cerenovus). Imperative Care is listed as an emerging player.
Does Vicora have an API?
No public API is recorded for Vicora.
What industry is Vicora in?
Vicora's product category is Vascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.